


Supplementary Table 1: Inclusion/exclusion criteria and outcomes of the network meta-analysis

Inclusion and exclusion criteria
<p>Studies included if:</p> <ul style="list-style-type: none">• Randomized Clinical trials• Published in English• Published in the last 10 years (from date of literature search) <p>Studies excluded if:</p> <ul style="list-style-type: none">• Non-randomized controlled trails• Published in language other than English• Published before more than 10 years (from date of literature search)
Outcomes
<ul style="list-style-type: none">• Major bleeding• Clinically relevant non-major (CRNM) bleeding• All-cause mortality• Stroke• Myocardial infarction (MI)• Stent thrombosis

Supplementary Table 2: Risk of bias for the included randomized controlled trials


	PIONEER AF-PCI	RE-DUAL PCI	AUGUSTUS	ENTRUST AF-PCI
Random sequence generation (<i>Selection bias</i>)	+	+	+	+
Allocation concealment (<i>Selection bias</i>)	+	+	+	+
Blinding of participants and personnel (<i>Performance bias</i>)	+	+	+	+
Incomplete outcome data (<i>Attrition bias</i>)	+	+	+	+
Selective reporting (<i>Reporting bias</i>)	+	+	+	+
Other sources of bias	+	+	+	+

(+) denotes low risk of bias, blank denotes unclear risk of bias, and (-) denotes high risk of bias.




Supplementary Figure 1: The rankogram for different agents in the all-cause mortality outcome

VKA: Vitamin K antagonist, P2Y12i: P2Y₁₂ inhibitor, LD: Low dose.




Supplementary Figure 2: The rankogram for different agents in the stroke outcome

VKA: Vitamin K antagonist, P2Y12i: P2Y₁₂ inhibitor, LD: Low dose.



Supplementary Figure 3: The rankogram for different agents in the Myocardial Infarction outcome

VKA: Vitamin K antagonist, P2Y12i: P2Y₁₂ inhibitor, LD: Low dose.



Supplementary Figure 4: The rankogram for different agents in the stent thrombosis outcome

VKA: Vitamin K antagonist, P2Y12i: P2Y₁₂ inhibitor, LD: Low dose.